PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PROCEPT BioRobotics (Nasdaq: PRCT) management will join a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. The discussion is scheduled for 3:30 p.m. ET in New York City, where the company will also host in-person meetings.
A live webcast will be available on the company's investor website, with a replay available for at least 90 days after the event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will be participating in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference in New York City on Wednesday, December 2, 2026, at 3:30 p.m. ET / 12:30 PM PT. The company will also be hosting in person meetings.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Media Contact: Pooja Rao, media@procept-biorobotics.com
Investor Contact: Marissa Bych, ir@procept-biorobotics.com